drugset
drugset / Trial / NCT07641179

A Study to Evaluate MAR002 for Acromegaly

NCT07641179 ↗

Phase 2 Not yet recruiting 72 enrolled Marea Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly

Timeline

Start
2026-07
Primary completion
2027-08
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MAR002 Unknown — Subcutaneous

Indications

acromegaly